Skip to content
OpenCapital
Get started

Allarity Therapeutics, Inc. ALLR Q4 2024 Annual earnings

Reported April 4, 2025 · Before market open

Revenue$6.0K
EPS-$4.73Beat by $3.37
EPS estimate-$8.10

Next report

Aug 21, 2026 (In 3 weeks)
Revenue estimate$25.0K
EPS estimate-$0.25

Versus estimates

Revenue

Q1 2026$25.0KIn lineQ4 2025$320.0KIn line
Q4 2024$6.0K

Diluted EPS

Q1 2026-$0.17Beat by $0.05Q4 2025-$0.19Beat by $0.03Q3 2025-$0.19Beat by $0.04Q2 2025-$0.15Beat by $0.06Q1 2025-$0.25
Q4 2024-$4.73Beat by $3.37

Ask the moment Allarity Therapeutics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Allarity Therapeutics, Inc. report Q4 2024 earnings?
Allarity Therapeutics, Inc. (ALLR) reported Q4 2024 earnings on April 4, 2025 before market open.
What were Allarity Therapeutics, Inc.'s Q4 2024 revenue and EPS?
Allarity Therapeutics, Inc. reported revenue of $6.0K and eps of $-4.73 for Q4 2024.
Did Allarity Therapeutics, Inc. beat estimates in Q4 2024?
EPS beat the consensus estimate of $-8.10 by $3.37.
How did Allarity Therapeutics, Inc.'s Q4 2024 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 94.6% from $112.0K a year earlier and eps grew 97.3% from $-175.51.
Where can I find Allarity Therapeutics, Inc.'s Q4 2024 SEC filings?
You can read the 10-K periodic report (0001437749-25-010198) directly on SEC EDGAR. The filing index links above go to sec.gov.